KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Byoung Chul Cho, Rama Balaraman, Hua-Jun Chen, Xinmin Yu, Adewale Fawole, Zhi-Gang Liu, Jiliang Zhang, Long Wu, Bin Yang, Jennifer L Leddon, John Hamm, Yanjing Huang, Lin Wu, Pinhua Pan, Preet Singh, Andrew Beardsley, Fadi Kayali, Ardalan Davarifar, Ki Hyeong Lee, Keon-Uk Park, Youngjoo Lee, Luchun Li, Xicheng Wang, Meili Sun, Yan Yu, Vikram Jain, Svetlana Shpyro, Qiong Wang, Michael Wenger, Uğur Şahin, Sergey Efuni, Shiling Song, Kun He, Pan Zheng, Yang Liu, Kai He, Tianhong Li, Mark A Socinski, Yi-Long Wu

Nat Med 32(6) 2245-2253

PMID41896648
PMCIDPMC13278949
DOI10.1038/s41591-026-04323-8
发表日期2026-03-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PRESERVE-003 is a two-stage phase 3 trial evaluating gotistobart (BNT316/ONC-392), a novel pH-sensitive anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody that selectively depletes regulatory T cells within the tumor microenvironment, in patients with metastatic squamous non-small cell lung cancer (sqNSCLC) without actionable genomic alterations who progressed on programmed cell death protein/programmed death ligand 1 inhibitor/platinum-based chemotherapy-a population with a poor prognosis. Here we report on stage 1, which aimed to confirm the dose and assess the preliminary efficacy (primary outcome: overall survival; secondary outcomes: progression‑free survival, objective response rate and duration of response) and safety of gotistobart compared to docetaxel. Patients with sqNSCLC were randomized (1:1) to gotistobart (6 mg kg-1 with two 10 mg kg-1 loading doses every 3 weeks (N = 45)) or docetaxel (75 mg m-2 every 3 weeks (N = 42)). After a median follow-up of 14.5 months, median overall survival was not reached with gotistobart (95% confidence interval (CI) 9.3 to not evaluable) versus 10.0 months (95% CI 6.2 to 11.9 months) with docetaxel (hazard ratio 0.46, 95% CI 0.25 to 0.84, nominal two-sided P = 0.0102). Safety was manageable, with grade ≥3 treatment-related adverse events in 42% and 49% of patients receiving gotistobart and docetaxel, respectively. Stage 1 results suggest that gotistobart monotherapy can provide clinically meaningful benefit for patients with programmed cell death protein/programmed death ligand 1-resistant and chemotherapy-resistant metastatic sqNSCLC. ClinicalTrials.gov identifier: NCT05671510 .

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2. OS and PFS. a , b , Kaplan–Meier estimates of OS ( a ) and PFS (investigator assessment) ( b ) in patients with sqNSCLC. The numbers and percentages of patients with an OS event and those alive as of the data cutoff are listed in the tables. The dashed line indicates the 12-month OS rate, and the crosses indicate censored patients. Seven patients withdrew from the study before death and were censored at their last known alive date: three patients in the gotistobart arm and four patients in the docetaxel arm. The P value was nominal, that is, not from formal hypothesis testing. a The duration of follow-up in months was calculated using a reversed Kaplan–Meier analysis, with OS events censored and deaths treated as events. IQR, interquartile range.

A

OS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Patient disposition. a Four patients with sqNSCLC and six patients with non-sqNSCLC were randomized to gotistobart 3 mg kg −1 before termination by the DMC.
非 KM Figure
Fig. 3Fig. 3. Antitumor efficacy. a , b , Tumor response: the best percentage change from baseline by treatment (investigator assessment) ( a ) and percentage change from baseline over time by treatment (investigator assessment) ( b ) in patients with sqNSCLC. PD, progressive disease; PR, partial response; SD, stable disease.
非 KM Figure